Medtronic Reports Strong Q1 FY27 Results & Raises Full-Year Guidance
Medtronic plc
Subscribe to track MDT
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Medtronic Reports Strong Q1 FY27 Results & Raises Full-Year Guidance
Company: Medtronic plc (MDT)
Form: 8-K | Filed: September 1, 2026
Significance: Medium
Key Highlights: • Q1 FY27 Worldwide Revenue: $9.756B (+13.7% YoY reported & organic) • GAAP Diluted EPS: $1.14 (+40.7% YoY) | Non-GAAP Diluted EPS: $1.45 (+15.1% YoY) • Raised FY27 Guidance: Organic revenue growth raised to 7.25%–7.75%; Non-GAAP EPS raised to $5.94–$6.00 • Cardiovascular grew 18.9% organically; Neuroscience up 9.3%; Medical Surgical up 10.2%
Market Context: Medtronic delivered broad-based portfolio outperformance and raised full-year fiscal 2027 top-line and bottom-line outlooks amid strong procedural volumes and key product adoption.
Comprehensive Analysis
SEC Filing Analysis: Medtronic plc (NYSE: MDT)
Executive Summary
- Trading Significance: Medium
- Key Takeaway: Medtronic reported robust Q1 FY27 financial results beating guidance midpoints and raised full-year revenue growth and EPS outlooks.
- Market Impact: Favorable operational beat and guidance upward revision indicate strengthening fundamentals across core medtech segments.
Company Information
| Field | Value |
|---|---|
| Company | Medtronic plc |
| Ticker Symbol | MDT |
| CIK | 0001613103 |
| Industry | Electromedical & Electrotherapeutic Apparatus |
Insider Information
| Field | Value |
|---|---|
| Name | N/A (Corporate 8-K Filing) |
| CIK | N/A |
| Title/Position | N/A |
| Relationship | N/A |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 8-K (Item 2.02 - Results of Operations and Financial Condition) |
| Transaction Date | N/A |
| Transaction Code | N/A |
| Security Type | Ordinary Shares |
| Shares Involved | N/A |
| Price Per Share | N/A |
| Total Value | N/A |
| Shares Owned After | N/A |
| Ownership Type | N/A |
Financial & Operational Assessment
Q1 FY27 Performance Overview
- Worldwide Revenue: $9.756 billion, increasing 13.7% YoY (reported and organic), approximately 200 bps above the guidance midpoint.
- Diluted EPS: GAAP EPS rose 40.7% to $1.14; non-GAAP diluted EPS reached $1.45 (+15.1% YoY).
- Segment Growth (Organic):
- Cardiovascular: $3.927 billion (+18.9% organic), driven by Electrophysiology (+29.1%) and Interventional Cardiology (+6.5%).
- Neuroscience: $2.678 billion (+9.3% organic), propelled by Cranial & Spinal Technologies (+12.9%).
- Medical Surgical: $2.279 billion (+10.2% organic), led by Acute Care & Monitoring (+14.2%).
- Diabetes: $843 million (+14.9% organic).
Updated FY27 Guidance
- Organic Revenue Growth: Raised to 7.25% – 7.75% (from prior 6.75% – 7.25%).
- Diluted Non-GAAP EPS: Raised to $5.94 – $6.00 (from prior $5.90 – $6.00).
Market Impact Analysis
- Stock Impact Direction: Positive to Neutral
- Reasoning: A quarterly top- and bottom-line beat combined with raised full-year revenue and earnings guidance provides a solid catalyst for investor sentiment, partially offset by macro considerations and extra fiscal week calendar adjustments ($570M organic benefit).
- Sentiment Indicator: Moderately Bullish / Constructive
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.
The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.
Always do your own due diligence and consult a licensed professional.